Other Assets

Other assets consist of the following (in thousands):

	June 30,		March 31,
	2017		2017
	(unaudited)
Marketable equity securities	$	1,821	$	1,771
Long-term equity method investments		12,145		11,589
Other items, including cost method investments		8,236		4,615
Total	$	22,202	$	17,975

Available-for-Sale Investments

Marketable equity securities and auction rate preferred securities are designated as available-for-sale and are reported at fair value with unrealized gains and losses, net of income taxes, recorded in other comprehensive income (loss). Realized gains and losses (calculated as proceeds less specifically identified costs) and declines in value of these investments judged by management to be other than temporary, if any, are included in other income (expense), net.

Equity Method Investments

We have equity interests in Powersem GmbH, or Powersem, a semiconductor manufacturer based in Germany, EB Tech Ltd., or EB Tech, a radiation services provider based in South Korea and Automated Technology, Inc., or ATEC, an assembly and test services provider in the Philippines. These investments are accounted for using the equity method. For the

three

months ended

June 30, 2017

and

2016,

we recorded an immaterial amount of our proportionate share of the affiliates’ gains and losses under the equity method of accounting. The carrying values of our investments in Powersem, EB Tech and ATEC at

June 30, 2017

were

$2.7

million,

$2.6

million and

$6.8

million, respectively. The carrying values of our investments in Powersem, EB Tech and ATEC at

March

31,

2017

were

$2.5

million,

$2.6

million and

$6.5

million, respectively.

Cost Method Investments

During the

three

months ended

June 30, 2017

and during fiscal

2017,

we made investments in privately-held companies. Those investments are accounted for under the cost method as they do

not

qualify for the fair value method or for another accounting method. As of

June 30, 2017

and

March 31, 2017,

the carrying values of those investments were

$4.1

million and

$3.1

million, respectively. We do

not

estimate the fair value of those cost method investments because determining the fair value is

not

practicable.